Phosphodiesterase
Enzyme (PDE) Inhibitors Market - Global Industry Insights, Trends, Outlook,
and Opportunity Analysis, 2018-2026
Phosphodiesterase are a diverse
family of enzymes (11 isoenzymes) that play a key role in regulating
intracellular levels of secondary messengers - cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate. These enzymes identified to be
pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat
various diseases such as cardiovascular, respiratory and erectile dysfunction.
Distinct distribution of all the types of isoenzymes has provided possibilities
for selective target therapies.
The global phosphodiesterase
enzyme inhibitors market can be better analyzed by classifying it into two
classes as selective phosphodiesterase enzyme inhibitors and non-selective
phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two
most commonly used non-selective phosphodiesterase enzyme inhibitors for
treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent
of selective phosphodiesterase enzyme inhibitors has made a great impact in the
medical treatment sector. Increasing understanding of the individual PDE
isoforms has and will result in the emergence of better therapeutic drugs.
Viagra (Sildenafil) is the best example to substantiate the success and impact
of PDE inhibitors.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/172
The global phosphodiesterase
enzyme inhibitors market is majorly driven by PDE-5 inhibitors realizing the
success of blockbuster drugs in these segment.
Increasing product developments
to further improvise the phosphodiesterase enzyme inhibitors market outlook
The global phosphodiesterase
enzyme inhibitors market has recently gained traction on account of the
blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged
pharmaceutical companies to research on other PDE inhibitor class. In addition,
research on extended use of approved PDE inhibitors is anticipated to benefit
the drug in long term and contribute to the increasing revenues of PDE
inhibitors market.
Researchers from the John Hopkin
University reviewed the trials of PDE-5 inhibitors in pediatric patients with
pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be
safely prescribed to infants, neonates and children with primary and secondary
pulmonary hypertension (2017).
Besides, PDE-5 inhibitor
sildenafil accidently developed for treating angina, was also found to be
effective in erectile dysfunction and now is observed to benefit heart attack
patients. Researchers at Karolinska Institutet, Sweden reported in March 2017
that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of
death of hospitalization for heart failure in men who have had one heart attack
in their lifetime.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/phosphodiesterase-enzyme-inhibitors-market-172
Pfizer, Inc. received FDA
approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the
treatment of mild to moderate atopic dermatitis. Eucrisa the first
non-steroidal topical monotherapy for skin disorder.
Many such product developments
would be augmenting the global PDE inhibitors market growth in near future.
New products are primarily
targeted in develop economies like North America, Europe and Japan. However,
product approval in emerging nations such as India, China, Brazil, Russia,
Argentina, and Indonesia would potentially favorable for the market players.
Increasing healthcare expenditure and large target population base would
support the growth of PDE inhibitors market in these nations. However, market
players need to be cautious about uncertain regulatory conditions favoring the
economic status and healthcare need of the large patient population.
Some of the key players operating
in the global phosphodiesterase enzyme inhibitors market include Pfizer, Inc.,
AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist
Pharmaceuticals.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/172
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200 Seattle,
WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment